



FOR IMMEDIATE RELEASE

March 16, 2009

Methapharm Inc. announces Canadian Distribution of Dantrium[®] (dantrolene sodium)

JHP Pharmaceuticals, LLC (JHP) announced today that Methapharm Inc. will assume the role of distributor of the Dantrium[®] (dantrolene sodium) product line. US and Canadian rights to the Dantrium product line were acquired by JHP from Proctor and Gamble Pharmaceuticals --- on August 18, 2008. In its intravenous form, Dantrium is used to treat malignant hyperthermia (a life-threatening reaction to certain gaseous anesthetics) and in its oral form, it is indicated for the control of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis).

Methapharm will begin distributing Dantrium[®] (dantrolene sodium) IV and capsules effective today.

About Methapharm Inc.

Methapharm, headquartered in Brantford, Ontario is a privately held, full-service pharmaceutical distribution company offering sales and marketing, regulatory services, market access, and distribution capabilities for product partnership opportunities. Operating in the United States and Canada, we are focused on the commercialization and marketing of niche pharmaceutical products and related medical devices in either country.

About JHP Pharmaceuticals, LLC

JHP, headquartered in New Jersey, is a specialty pharmaceutical company which manufactures and sells pharmaceutical products, primarily aseptic injectable products into the hospital segment, and provides contract manufacturing of sterile products for innovator pharmaceutical companies. JHP is a private company wholly owned by JHP Holdings, LLC whose equity owners are Morgan Stanley Principal Investments, Peter Jenkins and Stuart Hinchin.

For more information:

Chris Calenti
General Manager
Methapharm Inc.
Tel: 519-751-3602

Stuart Hinchin
President
JHP Pharmaceuticals, LLC
Tel: +1 201-306-4412

[®] Dantrium is a registered trademark of JHP Pharmaceuticals, LLC.